Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew J Ellis

Showing results (151-160 of 285) with videos related to

Pageof 29
Sort By:
Cancer Medicine|September 5, 2015
Associations among ancestry, geography and breast cancer incidence, mortality, and survival in Trinidad and TobagoWayne A Warner, Robert L Morrison, Tammy Y Lee, et al.
Scientific Reports|October 23, 2022
Personalized ctDNA micro-panels can monitor and predict clinical outcomes for patients with triple-negative breast cancerErica K Barnell, Bryan Fisk, Zachary L Skidmore, et al.
Oncotarget|February 23, 2018
ZB716, a steroidal selective estrogen receptor degrader (SERD), is orally efficacious in blocking tumor growth in mouse xenograft modelsShanchun Guo, Changde Zhang, Melyssa Bratton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 21, 2015
Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast CancerSuzanne E Wardell, Matthew J Ellis, Holly M Alley, et al.
Breast Cancer Research and Treatment|October 22, 2009
Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancerMatthew J Ellis, Li Lin, Robert Crowder, et al.
Molecular Genetics & Genomic Medicine|May 18, 2019
Copy number alterations associated with clinical features in an underrepresented population with breast cancerRaquel M Rodrigues-Peres, Benilton de S Carvalho, Meenakshi Anurag, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 20, 2012
A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifenStephen K Chia, Vivien H Bramwell, Dongsheng Tu, et al.
Clinical Transplantation|January 10, 2021
African Americans' discussions about living-donor kidney transplants with family or friends: Who, what, and why not?Nicole DePasquale, Matthew J Ellis, Debra L Sudan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2016
Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)Maura N Dickler, William T Barry, Constance T Cirrincione, et al.
International Journal of Radiation Oncology, Biology, Physics|July 12, 2024
Increased Synthetic Cytotoxicity of Combinatorial Chemoradiation Therapy in Homologous Recombination Deficient TumorsJennifer Ma, Rachna Shah, Andrew C Bell, et al.
Pageof 29

Showing results (151-160 of 285) with videos related to

Sort By:
Pageof 29
Cancer Medicine|September 5, 2015
Associations among ancestry, geography and breast cancer incidence, mortality, and survival in Trinidad and TobagoWayne A Warner, Robert L Morrison, Tammy Y Lee, et al.
Scientific Reports|October 23, 2022
Personalized ctDNA micro-panels can monitor and predict clinical outcomes for patients with triple-negative breast cancerErica K Barnell, Bryan Fisk, Zachary L Skidmore, et al.
Oncotarget|February 23, 2018
ZB716, a steroidal selective estrogen receptor degrader (SERD), is orally efficacious in blocking tumor growth in mouse xenograft modelsShanchun Guo, Changde Zhang, Melyssa Bratton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 21, 2015
Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast CancerSuzanne E Wardell, Matthew J Ellis, Holly M Alley, et al.
Breast Cancer Research and Treatment|October 22, 2009
Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancerMatthew J Ellis, Li Lin, Robert Crowder, et al.
Molecular Genetics & Genomic Medicine|May 18, 2019
Copy number alterations associated with clinical features in an underrepresented population with breast cancerRaquel M Rodrigues-Peres, Benilton de S Carvalho, Meenakshi Anurag, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 20, 2012
A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifenStephen K Chia, Vivien H Bramwell, Dongsheng Tu, et al.
Clinical Transplantation|January 10, 2021
African Americans' discussions about living-donor kidney transplants with family or friends: Who, what, and why not?Nicole DePasquale, Matthew J Ellis, Debra L Sudan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2016
Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)Maura N Dickler, William T Barry, Constance T Cirrincione, et al.
International Journal of Radiation Oncology, Biology, Physics|July 12, 2024
Increased Synthetic Cytotoxicity of Combinatorial Chemoradiation Therapy in Homologous Recombination Deficient TumorsJennifer Ma, Rachna Shah, Andrew C Bell, et al.
Pageof 29